Trial Profile
A Phase III trial of selumetinib in patients with KRAS-mutant non small cell lung cancer
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 15 Apr 2015
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Apr 2015 New trial record